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Background:  Left ventricular assist devices are routinely placed for end stage non-ischemic cardiomyopathy patients. Myocardial recovery 
on therapy is highly variable. Next Generation Sequencing gives us the ability to test for a wide range of damaging mutations. Our objective 
was to determine the association between damaging cardiac gene variants and myocardial recovery in non-ischemic cardiomyopathy 
patients undergoing LVAD placement. 
methods:  Explanted human heart tissue procured at the time of LVAD placement was obtained from the heart tissue bank at the University 
of Nebraska. Cardiomyopathy associated genes were sequenced utilizing an inherited disease panel (Ion Torrent). Genomic DNA was 
isolated from tissues using the All DNA/RNA mini kit (Qiagen). 10 ng of DNA was amplified by PCR using inherited diseases panel primer 
pools. The amplicons were then ligated to adapters and additional library amplification was done by emulsion PCR on Ion Sphere particles 
(ISPs). Sequencing was performed on PGM sequencer (Ion torrent) using the Ion 316 chip. The Ion Torrent browser suite was used to 
map the reads and call the variants. The identified single nucleotide polymorphisms, insertions, and deletions were then annotated and 
characterized with ANNOVAR. Variants with a population frequency of less than or equal to 1% were identified and analyzed utilizing an 
open source integrative genomics viewer. Amino acid substitution effects on protein function were determined by a bioinformatics algorithm. 
Myocardial recovery was defined as an improvement in EF to greater than 45% at 3 months post implant.
results:  Our sample population included 12 males and 4 females with a mean age of 49 and an average LVEF at presentation of 17%. 
Damaging cardiac gene variants were present in 10/14 patients. Only 1 of the 10 patients with damaging cardiac gene variants improved 
their ejection fraction to greater than 45% post LVAD. 4 of the 5 patients without mutations improved their ejection fraction to greater than 
45%, p-value=.03
conclusion:  Damaging cardiac gene variants are common in this population. These results suggest that cardiac gene variation may 
portend a worse prognosis in advanced heart failure patients. 
